

Warsaw, October 20, 2025

Shareholders

Orphinic Scientific Spółka Akcyjna

NOTICE

**of the convening of Extraordinary General Meeting of Shareholders of
Orphinic Scientific Spółka Akcyjna with its registered office in Warsaw**

Acting pursuant to Article 399 §1 of the Commercial Companies Code and § 9(4) in conjunction with § 9(1)(h) of the Articles of Association of Orphinic Scientific S.A. with its registered office in Warsaw (the "Company"), the Management Board of the Company hereby convenes an Extraordinary General Meeting of the Company ("Meeting") on **November 4, 2025, at 10:00 a.m.**, at the **Notary Office of Rafat Brandt, Joanna Okońska, Sebastian Chaber Notaries s.c., ul. Mokotowska 46A lok.27.**, with the following agenda:

1. *Opening of the Meeting.*
2. *Election of the Chairperson of the Meeting.*
3. *Confirmation of the proper convening of the General Meeting and its capacity to adopt resolutions.*
4. *Adoption of the agenda.*
5. *Adoption of a resolution on the appointment of a Member of the Company's Supervisory Board.*
6. *Adoption of a resolution on amending the Company's Articles of Association to grant additional powers (impose additional duties) on the Supervisory Board.*
7. *Free applications.*
8. *Closing of the Meeting.*

In connection with the announcement by the Management Board of the Company of the convening of the Extraordinary General Meeting of Orphinic Scientific Spółka Akcyjna on November 4, 2025, and the

intention to adopt a resolution regarding amendments to the Company's Articles of Association (Item 6 of the agenda), the Management Board of the Company presents below the current wording of the relevant provision of the Articles of Association and the scope of the proposed amendments.

Previous wording of § 10(5):

"5. The duties of the Supervisory Board shall include:

- a) assessing the Management Board's report on the Company's operations and the financial statements for the previous financial year in terms of their compliance with the books and documents, as well as with the actual state of affairs, and the Management Board's proposals concerning the distribution of net profit and coverage of net loss, as well as submitting an annual written report on the results of this assessment and the activities of the Supervisory Board to the General Meeting,*
- b) analyzing and assessing the Company's current operations,*
- c) approving annual financial plans (operating budget) and strategic economic plans (business plan),*
- d) considering matters submitted by the Management Board,*
- e) selecting an audit firm to audit the financial statements,*
- f) appointing and dismissing members of the Management Board,*
- g) establishing the rules for remunerating members of the Management Board.*

We propose adding letter h to the current § 10 section 5, so that it reads as follows:

"5. The duties and powers of the Supervisory Board shall include:

- a) assessing the Management Board's report on the Company's operations and the financial statements for the previous financial year in terms of their compliance with the books and documents, as well as with the actual state of affairs, and the Management Board's proposals concerning the distribution of net profit and coverage of net loss, as well as submitting an annual written report to the General Meeting on the results of this assessment and the activities of the Supervisory Board,*
- b) analyzing and assessing the Company's current operations,*
- c) approving annual financial plans (operating budget) and strategic economic plans (business plan),*
- d) considering matters submitted by the Management Board,*
- e) selecting an audit firm to audit the financial statements,*
- f) appointing and dismissing members of the Management Board,*
- g) establishing the rules for remunerating members of the Management Board.*

- h) granting consent for VASA Therapeutics, Inc. with its registered office in Delaware (hereinafter: “VASA”) to perform specific legal or factual actions, where the need for VASA to obtain such consent arises from the legal relationship between VASA and the Company, in particular from the investment agreements concluded and the accompanying documentation.*

Management Board of Orphinic Scientific Spółka Akcyjna

Wojciech Ciesielski

Board Member

Artur Płonowski

Board Member